Dr. Mohammed Khanzada, MD
What this data tells you about Dr. Khanzada
Dr. Mohammed Khanzada is an optician in Texarkana, TX, with 20 years in practice. Based on federal Medicare data, Dr. Khanzada performed 6,754 Medicare services across 1,819 unique beneficiaries.
Between the years covered by Open Payments, Dr. Khanzada received a total of $208 from 8 pharmaceutical and/or device companies across 12 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in optician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Khanzada is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Drug screening test | 1,871 | $61 | $175 |
| Office visit, established patient (30-39 min) | 1,464 | $90 | $418 |
| Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 1,238 | $191 | $744 |
| Dexamethasone injection (steroid) | 930 | $0 | $125 |
| Remote patient monitoring device, 30 days | 295 | $33 | $187 |
| Remote patient monitoring management, 20 min/month | 196 | $37 | $161 |
| New patient office visit (45-59 min) | 113 | $120 | $542 |
| Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 102 | $151 | $578 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 83 | $196 | $1,124 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 83 | $103 | $587 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | 64 | $315 | $1,344 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | 64 | $174 | $1,543 |
| Testing for presence of drug, read by direct observation | 50 | $8 | $150 |
| Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | 38 | $12 | $56 |
| Injection of upper or middle spine facet joint using imaging guidance, single level | 36 | $215 | $617 |
| Injection of upper or middle spine facet joint using imaging guidance, second level | 36 | $110 | $315 |
| Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance | 33 | $159 | $549 |
| Injection of anesthetic agent and/or steroid into spine and pelvis nerve using imaging guidance | 22 | $214 | $702 |
| Destruction of upper or middle spinal facet joint nerves using imaging guidance, single facet joint | 18 | $333 | $1,352 |
| Destruction of upper or middle spinal facet joint nerves using imaging guidance, each additional facet joint | 18 | $201 | $1,300 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Khanzada is a clinical cardiology specialist, with above-average Medicare volume (top 11% in TX), and low-engagement industry engagement, with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Khanzada experienced with drug screening test?
Does Dr. Khanzada receive payments from pharmaceutical companies?
How do Dr. Khanzada's costs compare to other opticians in Texarkana?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology